Biosynthetic Semaglutide Cuts HbA1c by 1.86% and Weight by 7.8 kg in Real-World Use
A 30-week Pakistani multicentre study shows biosynthetic semaglutide delivers clinically meaningful glycemic and weight benefits in routine care.
Summary
A prospective, real-world study across multiple Pakistani clinics followed 217 adults with type 2 diabetes who started biosynthetic semaglutide for 30 weeks. Average HbA1c dropped from 9.27% to 7.41%, nearly 77% of patients achieved HbA1c below 8%, and average body weight fell by almost 8 kg. Over three-quarters of participants lost at least 5% of their body weight. Treatment satisfaction and physical quality of life also improved significantly. Side effects were mainly mild gastrointestinal complaints, and no severe hypoglycemia occurred. The findings suggest biosynthetic semaglutide performs comparably to branded semaglutide even in resource-limited healthcare settings, potentially expanding access to effective GLP-1 therapy for millions of patients globally.
Detailed Summary
GLP-1 receptor agonists like semaglutide have transformed type 2 diabetes management, but their high cost limits access in lower-income countries. Biosynthetic semaglutide — a more affordable version — has emerged as a potential solution, yet real-world evidence from cost-constrained settings has been scarce until now.
This prospective, non-interventional multicentre study enrolled 217 adults with type 2 diabetes across multiple outpatient clinics in Pakistan. Participants initiated biosynthetic semaglutide as part of routine care and were followed for 30 weeks. The primary outcome was change in HbA1c; secondary outcomes included body weight, waist circumference, patient-reported treatment satisfaction, and physical quality of life measured by validated instruments (DTSQs and SF-36v2).
The results were striking. Mean HbA1c fell from 9.27% at baseline to 7.41% at study end, a reduction of 1.86 percentage points. Roughly 77% of patients achieved HbA1c below 8% and nearly 39% reached the tighter target of below 7%. Mean body weight decreased by 7.84 kg, with 76.5% of patients achieving clinically meaningful weight loss of 5% or more. BMI and waist circumference also declined significantly. Patient-reported treatment satisfaction and physical quality-of-life scores improved, and the safety profile mirrored that of branded semaglutide — predominantly mild, non-serious gastrointestinal events with no severe hypoglycemia.
These findings carry important global implications. If biosynthetic semaglutide can replicate the efficacy and safety of branded formulations in real-world practice, it could dramatically widen access to GLP-1 therapy in South Asia, the Middle East, and beyond, where the diabetes burden is enormous but drug costs are prohibitive.
Caveats include the absence of a control group, the 30-week follow-up being relatively short, and the summary being based on the abstract alone. The lack of head-to-head comparison with branded semaglutide limits direct equivalence conclusions.
Key Findings
- HbA1c dropped by 1.86 percentage points (9.27% to 7.41%) over 30 weeks in real-world practice.
- 76.6% of patients achieved HbA1c below 8%; 38.7% reached the tighter target of below 7%.
- Average body weight fell by 7.84 kg; 76.5% of patients lost at least 5% of body weight.
- Treatment satisfaction and physical quality of life improved significantly alongside metabolic gains.
- No severe hypoglycemia occurred; adverse events were mostly mild gastrointestinal in nature.
Methodology
This was a 30-week prospective, multicentre, non-interventional observational study enrolling 217 adults with type 2 diabetes initiating biosynthetic semaglutide across routine outpatient clinics in Pakistan. Patient-reported outcomes were captured using validated tools (DTSQs and SF-36v2). The trial was registered in the Australian New Zealand Clinical Trials Registry.
Study Limitations
The study lacks a control or comparator arm, making it impossible to attribute outcomes solely to biosynthetic semaglutide versus other concurrent care changes. The 30-week observation window is insufficient to assess long-term cardiovascular or renal outcomes. This summary is based on the abstract only, as the full text was not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: